Physician profile
Patricia A Amerson
NPI 1508971425
$72,541.47
in general payments reported to CMS, 2019-2025
12 companies · $7,921 in 2025
The $7,921 reported for 2025 was more than what 99% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11K · 2022: $12K · 2023: $40K · 2024: $1,236 · 2025: $7,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $23K · Consulting Fee: $12K · Travel and Lodging: $12K · Food and Beverage: $1,930.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22,924.00 |
| Consulting Fee | $12,150.00 |
| Travel and Lodging | $11,988.19 |
| Food and Beverage | $1,929.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36,101.85 | 2021-2023 | |
| Csl Behring | $14,009.29 | 2021-2025 | Idelvion, Hemgenix |
| Genentech USA, INC. | $10,621.05 | 2021-2023 | Hemlibra |
| Hema Biologics, LLC | $6,058.62 | 2023 | Sevenfact |
| Novo Nordisk INC | $3,743.25 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $800.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $473.00 | 2022 | |
| Genentech, INC. | $209.05 | 2021-2025 | Hemlibra |
| Boston Scientific Corporation | $166.62 | 2023-2025 | Ams 700, Wavewriter Alpha Prime 16 |
| Abiomed | $137.17 | 2025 | |
| Pfizer INC. | $124.98 | 2025 | |
| Si-Bone, INC. | $96.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Amerson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.